Veracyte, Inc. revenue
Veracyte, Inc.'s revenue was $517m in fiscal 2025, up 16.0% on the year before. Since fiscal 2011 ($2.6m) it has grown at a compound 45.8% a year. Over the last twelve months it was $562m.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 12 | 22 | 38 | 50 | 65 | 72 | 92 | 120 | 117 | 220 | 297 | 361 | 446 | 517 | 562 |
| Growth on the year before | — | +339.6% | +88.2% | +74.5% | +29.6% | +31.5% | +10.6% | +27.9% | +30.8% | −2.4% | +86.8% | +35.1% | +21.8% | +23.5% | +16.0% | — |
| Gross profit | −0 | 4 | 9 | 22 | 28 | 40 | 44 | 59 | 84 | — | — | 176 | 230 | 298 | 363 | 403 |
| Gross margin | −10.6% | 34.8% | 42.4% | 56.5% | 56.6% | 60.9% | 60.8% | 64.0% | 70.0% | — | — | 59.2% | 63.6% | 66.9% | 70.1% | 71.7% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Testing | $493M | 94.2% | ▲ 17.7% |
| Products | $14.3M | 2.7% | ▲ 5.0% |
| Biopharmaceutical and Other | $9.7M | 1.8% | ▼ 26.5% |
| Biopharmaceutical and Other Biopharmaceutical Revenue (part of Biopharmaceutical and Other) | $6.5M | 67.6% | ▼ 8.6% |
| Biopharmaceutical and Other Contract Manufacturing and Testing (part of Biopharmaceutical and Other) | $3.1M | 32.4% | ▼ 47.9% |
| Testing Other | $6.2M | 1.2% | ▼ 47.5% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $497M | 96.0% | ▲ 17.3% |
| Outside the US | $20.5M | 4.0% | ▼ 7.6% |
From Veracyte, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Veracyte, Inc. | $562m | 17.3% | 19.6% |
| Azenta, Inc. | $614m | 4.9% | -0.9% |
| 10x Genomics, Inc. | $617m | -4.3% | 2.8% |
| Twist Bioscience Corp | $432m | 19.2% | 22.4% |
| Neogenomics Inc | $788m | 11.1% | 11.1% |
| Repligen Corp | $806m | 13.8% | 7.3% |
Compare with peers
- Azenta, Inc. revenue
- 10x Genomics, Inc. revenue
- Twist Bioscience Corp revenue
- Neogenomics Inc revenue
- Repligen Corp revenue
Head to head: AZTA vs VCYTTXG vs VCYTTWST vs VCYT
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies